Sandra Dai
Impact in
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research
-
- Lymphoma Diagnosis and Treatment
Papers in
- Genetics 11
- Chronic Lymphocytic Leukemia Research 11
-
- Lymphoma Diagnosis and Treatment 10
- Co-authors
- Carol Moreno (8 shared papers)James P. Dean (7 shared papers)Jan A. Burger (8 shared papers)Thomas J. Kipps (7 shared papers)Peter Hillmen (7 shared papers)Paul M. Barr (7 shared papers)Steven Coutré (6 shared papers)Alessandra Tedeschi (7 shared papers)
- Journals
- Journal of Clinical Oncology (3 papers)Blood (2 papers)HemaSphere (1 paper)American Journal of Hematology (1 paper)Leukemia (1 paper)
- Partner nations
- United StatesItalyUnited Kingdom
In The Last Decade
Sandra Dai
10 papers receiving 734 citations
Sandra Dai's Hit Papers
Peers
Comparison fields: 5 of 36
- Genetics 713
- Pathology and Forensic Medicine 575
- Hematology 189
- Gastroenterology 72
- Immunology 242
Countries citing papers authored by Sandra Dai
This map shows the geographic impact of Sandra Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Dai more than expected).
Fields of papers citing papers by Sandra Dai
This network shows the impact of papers produced by Sandra Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Dai. The network helps show where Sandra Dai may publish in the future.
Co-authors
The 25 scholars most cited alongside Sandra Dai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study Hit paper breakdown → | 2019 | 312 |
| 2 | Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma Hit paper breakdown → | 2019 | 307 |
| 3 | 2022 | 79 | |
| 4 | 2021 | 18 | |
| 5 | 2017 | 11 | |
| 6 | 2022 | 9 | |
| 7 | 2020 | 5 | |
| 8 | 2015 | 3 | |
| 9 | 2019 | 2 | |
| 10 | 2019 | 1 | |
| 11 | 2019 | 0 |
About Sandra Dai
Sandra Dai is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Gastroenterology and Immunology, having authored 11 papers that have together received 747 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (10 papers), Gastrointestinal Tumor Research and Treatment (3 papers), Chronic Myeloid Leukemia Treatments (3 papers), Immunodeficiency and Autoimmune Disorders (2 papers) and Immune Cell Function and Interaction (1 paper). The work is most often cited by research in Genetics (713 citations), Pathology and Forensic Medicine (575 citations), Hematology (189 citations), Gastroenterology (72 citations) and Immunology (242 citations). Sandra Dai has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include Carol Moreno, James P. Dean, Jan A. Burger, Thomas J. Kipps, Peter Hillmen, Paul M. Barr, Steven Coutré, Alessandra Tedeschi, David Simpson and Tadeusz Robak. Their work appears in journals such as Journal of Clinical Oncology, Blood, HemaSphere, American Journal of Hematology and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.